Villeroy & Boch AG

  • WKN: 765723
  • ISIN: DE0007657231
  • Land: Germany

Nachricht vom 30.06.2021 | 20:09

Villeroy & Boch AG: Villeroy & Boch significantly raises its annual forecast for 2021

Villeroy & Boch AG / Key word(s): Change in Forecast
Villeroy & Boch AG: Villeroy & Boch significantly raises its annual forecast for 2021

30-Jun-2021 / 20:09 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Villeroy & Boch significantly raises its annual forecast for 2021 

Mettlach, 30.06.2021 -  In view of the continued very positive business development in the first half of the year, the Management Board of Villeroy & Boch AG is raising the turnover and earnings forecasts for the full year. It now expects an increase in Group turnover to around EUR 885 million (previously: 5-10 % compared to the previous year) as well as an increase in the Group operating result from around EUR 50 million in the previous year to over EUR 75 million (previously: significantly disproportionate). The increase in the earnings forecast is based on the higher turnover expectation and on successfully implemented structural measures in both divisions, including the transformation and efficiency program started last year. 

Note: The interim report for Q2 2021 will be published on 20 July 2021 as scheduled and will contain detailed information on the business development in both divisions. 

Press Relations contact:  
Katrin May 
Head of PR 
Tel.: +49 (0) 68 64 - 81 27 14 

Investor Relations contact: 
Susanne Reiter 
Head of Corporate Treasury and Investor Relations 
Tel.:  +49 (0) 68 64 81 12 27 

30-Jun-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021